Spinal gabapentin has been known to show the antinociceptive effect. Although several assumptions have been suggested, mechanisms of action of gabapentin have not been clearly established. The present study was undertaken to examine the action mechanisms of gabapentin at the spinal level. Male SD rats were prepared for intrathecal catheterization. The effect of gabapentin was assessed in the formalin test. After pretreatment with many classes of drugs, changes of effect of gabapentin were examined. General behaviors were also observed. Intrathecal gabapentin produced a suppression of the phase 2 flinching, but not phase 1 in the formalin test. The antinociceptive action of intrathecal gabapentin was reversed by intrathecal NMDA, AMPA, D-serine, CGS 15943, atropine, and naloxone. No antagonism was seen following administration of bicuculline, saclofen, prazosin, yohimbine, mecamylamine, L-leucine, dihydroergocristine, or thapsigargin. Taken together, intrathecal gabapentin attenuated only the facilitated state. At the spinal level, NMDA receptor, AMPA receptor, nonstrychnine site of NMDA receptor, adenosine receptor, muscarinic receptor, and opioid receptor may be involved in the antinociception of gabapentin, but GABA receptor, L-amino acid transporter, adrenergic receptor, nicotinic receptor, serotonin receptor, or calcium may not be involved.
INTRODUCTION
Gabapentin is an anticonvulsant that was synthesized as a structural analog to -aminobutyric acid (GABA) (1). Intrathecal or systemic delivery of gabapentin diminishes hyperalgesia in tissue injury pain models without affecting acute noxious stimuli threshold (2, 3) . Furthermore, the antinociceptive effect of gabapentin is more powerful after intrathecal rather than systemic administration (4, 5) . These findings suggest that gabapentin may alter the facilitated state and the major site of action of gabapentin may be the spinal cord. Although the mechanisms of action of gabapentin are not clear, the relations to specific receptors (1, 2) or substances (6), L-amino acid transporter (7), or voltage-dependent calcium channel (8) has been proposed as the sites of action of gabapentin.
Recently, understanding of neurotransmitters and systems such as serotonergic, adrenergic, cholinergic, and purinergic receptors involved in nociceptive modulation in the spinal cord has been increased (9) (10) (11) (12) .
The formalin test is an experimental model which shows acute nociception followed by facilitated state which occurs secondary to the persistent afferent input generated by a local tissue injury.
Thus, the aim of the present study was to observe the effect of intrathecal gabapentin in the formalin test and to further evaluate the mechanisms of action of gabapentin at the spinal level.
MATERIALS AND METHODS
The studies were conducted under a protocol approved by the Institutional Animal Care Committee, Research Institute of Medical Science, Chonnam National University.
Male Sprague-Dawley rats (250-300 g) were used. Rats were housed in group cages on a 12-h night/day cycle with access to food and water at all times. For drug administration, an intrathecal catheter was implanted during enflurane anesthesia, as previously described (13) .
A polyethylene (PE-10) catheter was advanced caudally by 8.5 cm through an incision in the atlantooccipital membrane to the lumbar enlargement. The exterior part of the catheter was tunneled subcutaneously and exited at the top of head and plugged with a piece of steel wire. The skin was closed with 3-0 silk sutures. Rats showing neurologic deficits postoperatively were sacrificed immediately. After surgery, rats were kept in individual cages and allowed to recover for 4-5 days.
The following drugs were used in this study: gabapentin Biochemical Internationals [RBI] , Natick, MA, U.S.A.), AMPA (alpha-amino-3-hydroxy-5-methtyl-4-isoxazolepropionate RBI), L-leucine (Sigma), bicuculline (Sigma), saclofen (RBI), prazosin hydrochloride (Sigma), yohimbine hydrochloride (Sigma), atropine sulfate (RBI), mecamylamine hydrochloride (RBI), CGS 15943 (RBI), naloxone hydrochloride (Sigma), dihydroergocristine methanesulfonate (RBI), and thapsigargin (RBI). CGS 15943, AMPA, and thapsigargin were dissolved in DMSO. Yohimbine and dihydroergocristine were dissolved in distilled water. Saclofen and prazosin were dissolved in 0.1 N NaOH and methyl alcohol, respectively. Other drugs were prepared by dissolving them in normal saline. Intrathecal administration of drugs was performed using a hand-driven, gear-operated syringe pump. All the drugs were delivered in a volume of 10 L solution, followed by an additional 10 L of normal saline to flush the catheter.
Pinna reflex, corneal reflex, and motor function were examined at 5, 10, 20, 30, 40, 50, and 60 min after intrathecal administration of gabapentin (300 g, n=5). Motor function was assessed by placing reflex, stepping reflex, and righting reflex.
For the nociceptive stimulus, 50 L of 5% formalin solution was injected subcutaneously into the plantar surface of the hindpaw using a 30 gauge needle. The formalin injection produces a characteristic pain behavior, biphasic flinching/shaking of the injected paw. Such pain behavior was therefore quantified by periodically counting the incidences of spontaneous flinching/shaking of the injected paw. The numbers of flinching were counted for 1-min periods at 1 and 5 min and at 5-min intervals from 10 to 60 min. Two phases of spontaneous flinching were observed after the formalin injection. Phase 1 and phase 2 were defined as 0-9 and 10-60 min after formalin injection, respectively. After the observation period of 1 hr, animals were immediately sacrificed.
Four to five days after surgery, rats were placed in a restraint cylinder for the experiment. After a 15-20 min adaptation, rats were then assigned to one of the drug treatment groups. Control experiments were performed with saline. The rats were used only once.
Time course and dose-response of the antinociceptive action of intrathecal gabapentin (10, 30, 100, 300 g) were determined. Gabapentin was administered 10 min before formalin injection.
To determine mechanisms of action of intrathecal gabapentin, many kinds of drugs were intrathecally given 10 min before the delivery of gabapentin (300 g), and formalin was injected 10 min later. Doses of drugs for antagonism were chosen based on the preliminary experiments, which were the maximal doses without affecting the control formalin response. Drugs were as follows: 1) GABA receptor; GABAA antagonist, bicuculline 0.3 g, GABAB antagonist, saclofen 30 g, 2) NMDA receptor; NMDA 0.1 g, 3) AMPA receptor; AMPA 0.003 g, 4) nonstrychnine site agonist of NMDA receptor; D-serine 100 g, 5) L-amino acid transporter competitor; L-leucine 100 g, 6) opioid receptor; opioid antagonist, naloxone 0.3 g, 7) adrenergic receptor; alpha-1 antagonist prazosin 3 g, alpha-2 antagonist, yohimbine 10 g, 8) cholinergic receptor; muscarinic antagonist, atropine 10 g, nicotinic antagonist, mecamylamine 10 g, 9) serotonin receptor; serotonin antagonist, dihydroergocristine 3 g, 10) adenosine receptor; adenosine antagonist CGS 15943 0.03 g, and 11) calcium uptake inhibitor; thapsigargin 0.3 g. Data are expressed as mean±SEM. The time response data are presented as the number of flinching. The dose-response data are presented as the percentage maximal possible inhibitory effect (%MPIE) in each phase.
The numbers of flinching were converted to %MPIE according to the following formula.
Sum of phase 1(2) count with drug %MPIE = ×100 Sum of phase 1(2) count in control group Dose-response data were analyzed by one-way analysis of variance (ANOVA) with Scheffe for post hoc.
Comparison of antagonism for the effect of gabapentin was analyzed by unpaired t-test. p<0.05 was considered statistically significant.
RESULTS
Neither change of pinna reflex and corneal reflex nor motor Gabapentin was intrathecally administared 10 min prior to injection of formalin into the hindpaw. Data are presented as the number of flinching. Each point on the graph represents mean ±SEM of 7-8 rats.
•
10 g 30 g 100 g 300 g impairment was noted after intrathecal administration of gabapentin. Gabapentin caused a decreased spontaneous activity and urination in some rats. Other abnormal behaviors were not observed. Subcutaneous injection of formalin into the hindpaw resulted in a biphasic flinching response of the injected paw. Fig. 1 shows the time course of the effect of intrathecal gabapentin, administered 10 min before formalin injection, in the formalin test. Intrathecal gabapentin did not alter the flinching response during phase 1. During phase 2, gabapentin produced a dose-dependent suppression of the flinching response (Fig. 2) .
The antinociceptive effects of intrathecal gabapentin were antagonized by intrathecal NMDA, AMPA, D-serine (Fig.  3) , CGS 15943, atropine, and naloxone (Fig. 4) , whereas bicuculline, saclofen (Fig. 5) , prazosin, yohimbine, mecamylamine (Fig. 6) , L-leucine, dihydroergocristine, and thapsigargin ( Fig. 7) did not reverse the antinociception of gabapentin.
DISCUSSION
In these experiments, intrathecal gabapentin did not affect the flinching response of phase 1 in the formalin test, but it decreased the phase 2 response. The results of gabapentin observed in this study were consistent with the previous findings (2, 14) . Therefore, these observations uphold that spinal gabapentin may alter the facilitated state evoked by persistent afferent input without effects on acute nociception. Although the antinociceptive mechanisms of spinal gabapentin remain unclear, several hypotheses have been suggested. It has been reported that gabapentin decreases glutamate concentrations and inhibits the release of glutamate and glutamatergic synaptic transmission presynatically (15) (16) (17) . Glutamate acts on the NMDA receptor and non-NMDA receptor and shows the excitatory effect (18, 19) . Further, AMPAevoked neuronal response is inhibited by gabapentin (20, 21) . These findings suggest that NMDA or AMPA receptor may be an action site of gabapentin. Our results that NMDA or AMPA attenuated the antinociceptive effect of gabapentin support these observations. Additionally, an agonist at the nonstrychnine site of NMDA receptor complex reversed the antinociception of gabapentin. This observation is also consistent with others (2, 22) . Therefore, NMDA receptor, AMPA receptor, and the nonstrychnine site of NMDA receptor may be action sites of gabapentin. Previous studies have shown that gabapentin increases the concentration, the rate of synthesis, and the release of GABA (1, 6) . However, intrathecal administration of GABAA or GABAB receptor antagonists did not reverse the antiallodynic effects produced by gabapentin (23) . In the current study, the antinociceptive action of gabapentin was not affected by either GABAA or GABAB receptor antagonists. Thus, it could be supposed that spinal GABA receptors may not be directly involved in the antinociceptive effect of intrathecal gabapentin. It has been proposed that gabapentin crosses several membrane barriers in the body via a specific amino acid transporter and competes with leucine, isoleucine, valine, and phenylalanine for transport (1, 7) . However, intrathecal L-leucine and BCH did not antagonize the antiallodynic effect of intrathecal gabapentin (24) . Hence, gabapentin may not have to enter nerve terminal or cells via L-amino acid transporter, which was supported by our results. The 2 subunit of voltage-sensitive calcium channels has been suggested as the binding site of gabapentin (8) . However, electrophysiological studies did not exhibit an action of gabapentin on voltage-sensitive calcium channels (25) . Although we did not investigate the role of calcium channels for the antinociception of gabapentin, it may not inhibit the calcium uptake. Gabapentin augments the level of serotonin (26) and intrathecal serotonin produces an antinociceptive effect being mediated through serotonin receptors (9) . Our study showed that the antinociceptive effect of gabapentin was not reduced by serotonin antagonist. Hence, the serotinin receptor does not seem to be involved in the effect of gabapentin. Spinal adrenergic receptors and cholinergic receptors are active to modulate the nociceptive information (10, 11) . In this study, the effect of gabapentin against nociception was not diminished by neither adrenergic antagonists nor nicotinic antagonist, while it was reduced by muscarinic antagonist. Accordingly, it may be conceivable that the antinociception of gabapentin is mediated by muscarinic receptor. Interestingly, naloxone reversed the effect of gabapentin, which implicates that there are certain connections between the effect of gabapentin and opioid receptors.
Adenosine is an endogenous purine compound with various effects on the modulation of nociceptive information at the spinal level (27) . The antinociception of intrathecal adenosine is mediated through adenosine receptors in dorsal horn of the spinal cord (12) . Both A1 and A2 subtypes of adenosine receptors have been identified in the substantia gelatinosa of the dorsal horn (28) . Considering that the antinociceptive effect of gabapentin was reversed by adenosine antagonist in the present study, it could be supposed that gabapentin may act on the adenosine receptors in the spinal cord.
In addition, intrathecal gabapentin is more potent than systemic injection in terms of antinociception (5, 6) , emphasizing that the spinal cord may be a major action site. The above-mentioned findings jointly suggest that gabapentin may act on a certain site or receptors at the spinal level and produce the antinociceptive effect.
In conclusion, spinal gabapentin exhibits antinociception in the facilitated state. These antinociceptive effects may be mediated through spinal NMDA receptor, AMPA receptor, nonstrychnine site of NMDA receptor, adenosine receptors, and muscarinic receptor.
